Is Target a Dividend King?
Popular retail giant Target Corporation (NYSE:TGT) has been in a…
Sell
22
SNDX Quote, Financials, Valuation and Earnings
Last price:
$12.61
Seasonality move
:
10.52%
Day range:
$12.06 - $12.90
52-week range:
$12.40 - $25.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.98x
Volume:
1.4M
Avg. volume:
2.4M
1-year change:
-43.35%
Market cap:
$1.1B
Revenue:
--
EPS (TTM):
-$3.63
Analysts' Opinion
-
Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.46, Syndax Pharmaceuticals has an estimated upside of 184.86% from its current price of $12.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $12.60.
Fair Value
-
According to the consensus of 11 analysts, Syndax Pharmaceuticals has 184.86% upside to fair value with a price target of $36.46 per share.
SNDX vs. S&P 500
-
Over the past 5 trading days, Syndax Pharmaceuticals has underperformed the S&P 500 by -9.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Syndax Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Syndax Pharmaceuticals has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Syndax Pharmaceuticals reported revenues of $12.5M.
Earnings Growth
-
Syndax Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Syndax Pharmaceuticals reported earnings per share of -$0.98.
Enterprise value:
686.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
-2.65x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-60.43%
Net Income Margin (TTM):
--
Return On Equity:
-67.33%
Return On Invested Capital:
-67.33%
Operating Margin:
-716.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $12.5M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$14M | -$194.1M | -$321.2M | -$56.4M | -$89.6M | |
| EBITDA | -$10.8M | -$175.9M | -$296.9M | -$51.1M | -$84.1M | |
| Diluted EPS | -$0.02 | -$2.58 | -$3.63 | -$0.73 | -$0.98 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $177.4M | $238.3M | $357.6M | $381M | $414.8M | |
| Total Assets | $179.3M | $239.5M | $359.7M | $399.2M | $425.8M | |
| Current Liabilities | $15.2M | $28.7M | $20.8M | $39.2M | $59.4M | |
| Total Liabilities | $47.3M | $40.5M | $21.6M | $40M | $59.4M | |
| Total Equity | $132M | $199M | $338.1M | $359.2M | $366.4M | |
| Total Debt | $20M | $20.5M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.1M | -$142.1M | -$258.9M | -$44.7M | -$62.3M | |
| Cash From Investing | -$108.5M | -$3.7M | $32.9M | $40.1M | $86.8M | |
| Cash From Financing | $118.5M | $169.2M | $264.4M | $1.9M | $3.1M | |
| Free Cash Flow | -$10.1M | -$142.1M | -$258.9M | -$44.7M | -$62.3M | |
SNDX
Sector
Market Cap
$1.1B
$46.7M
Price % of 52-Week High
50.51%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-42.45%
-33.88%
Beta (5-Year)
0.891
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$13.53
200-day SMA
Sell
Level
$19.36
Bollinger Bands (100)
Sell
Level
14.83 - 20.01
Chaikin Money Flow
Sell
Level
-29.6M
20-day SMA
Sell
Level
$13.33
Relative Strength Index (RSI14)
Sell
Level
35.29
ADX Line
Sell
Level
23.96
Williams %R
Buy
Level
-82.2222
50-day SMA
Sell
Level
$15.66
MACD (12, 26)
Sell
Level
-0.66
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
4.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Stock Forecast FAQ
In the current month, SNDX has received 10 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SNDX average analyst price target in the past 3 months is $36.46.
-
Where Will Syndax Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Syndax Pharmaceuticals share price will rise to $36.46 per share over the next 12 months.
-
What Do Analysts Say About Syndax Pharmaceuticals?
Analysts are divided on their view about Syndax Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Syndax Pharmaceuticals is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Syndax Pharmaceuticals's Price Target?
The price target for Syndax Pharmaceuticals over the next 1-year time period is forecast to be $36.46 according to 11 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SNDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Syndax Pharmaceuticals is a Buy. 10 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SNDX?
You can purchase shares of Syndax Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Syndax Pharmaceuticals shares.
-
What Is The Syndax Pharmaceuticals Share Price Today?
Syndax Pharmaceuticals was last trading at $12.61 per share. This represents the most recent stock quote for Syndax Pharmaceuticals. Yesterday, Syndax Pharmaceuticals closed at $12.60 per share.
-
How To Buy Syndax Pharmaceuticals Stock Online?
In order to purchase Syndax Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 15
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 15
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
65
DJT alert for Jan 15
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
